H.C. Wainwright analyst Ed Arce lowered his price target for Nabriva Therapeutics to $9 but maintains a Buy rating on the shares following the company’s analyst day. Nabriva is uniquely positioned to potentially launch two new classes of antibiotics in the U.S. by year end, Arce tells investors in a research note. The analyst says the company is approaching “several near-term value inflection points” towards its transition to a commercial stage biotech.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.